Submission on change to PBS listing Mepolizumab Injection - 15 Sep 2022
Submission from Allergy & Anaphylaxis Australia (A&AA): Change to PBS listing Mepolizumab Injection (Nucala®) to include use for people diagnosed with chronic rhinosinusitis with nasal polyps.
A&AA supports the PBS listing of Mepolizumab so that people with chronic rhinosinusitis with nasal polyps can, together with their treating medical specialist and surgeon, decide on the most appropriate treatment for them.
The listing of this medication would give these people hope for a more normal enjoyable life.
See the submission here: